IPG Photonics (IPGP)

NASDAQInformation TechnologySemiconductorsSnapshot 2026-10-23

$71.07+2.39%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge IPG Photonics’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-0.6%

+10% or more+5%0%−5%−10% or less

2.27 → 2.25 EPS · FY ending Dec 31, 2027 · 6 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 6 to 6; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q3
EPS	$0.3–$0.6non-GAAP	—
EBITDA	$35M–$51Mnon-GAAP	—
Operating expenses	$92M–$95Mnon-GAAP	—
FY 2026 · Q4
Revenue	—	290.52M
EPS	—	0.469
FY 2026 · Annual
Revenue	—	1.12B
EPS	—	1.104
FY 2027 · Annual
Revenue	—	1.24B
EPS	—	2.254

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
EPS around $0.40 next quarter	Profit per share is expected near $0.40 next quarter.	Broken	EPS falls below $0.25 next quarter	Diluted EPS: $0.12 per share FY2026-Q2; GAAP. Published target: 0.40 USD per share. The target does not explicitly identify fiscal versus calendar quarters. Source published Aug 4, 20260.12 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: c39ee3ee-f7f7-4d28-ae47-f189f3aea35b. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Gross margin near 38.5% next quarter	Profit per share is expected near $0.40 next quarter.	Under Pressure	Gross margin falls below 37% next quarter	Gross margin: 40.39% FY2026-Q2; GAAP. Published target: 38.5%. The target does not explicitly identify fiscal versus calendar quarters. Source published Aug 4, 202640.391988 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: c39ee3ee-f7f7-4d28-ae47-f189f3aea35b. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Resolve patent litigation with Trumpf	The company is resolving patent issues with Trumpf.	Recovered	New patent litigation or unresolved disputes persist beyond 2026	Litigation resolved May 2026 vs target by 2026 May 2026 8-K reports agreement with Trumpf to resolve and dismiss all patent litigation worldwide. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 quarters including 2026-Q1 and the March 2026 announcement. The litigation affects less than 1% of total sales and IPG is implementing contingency measures and appealing. The priority is recurring with ongoing legal developments, showing persistent focus but limited financial impact disclosed. Delivery assessment Oct 24, 2026
Revenue grows to about $275M next quarter	Gross margins improve to about 38.5% next quarter.	Broken	Revenue falls below $260M next quarter	Revenue: $278.58M FY2026-Q2; GAAP. Published target: ~$275M. The target does not explicitly identify fiscal versus calendar quarters. Source published Aug 4, 2026278,580,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: c39ee3ee-f7f7-4d28-ae47-f189f3aea35b. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$2.25

$2.14 → $2.25 · observed estimates

FY2027 revenue$1.24B

$1.21B → $1.24B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$2.14	$1,214,782,094	7 / 7
2026-07-25	$2.31	$1,214,782,130	7 / 9
2026-07-26	$2.31	$1,214,782,130	7 / 9
2026-07-27	$2.31	$1,214,782,130	7 / 9
2026-07-28	$2.14	$1,214,782,094	7 / 7
2026-07-29	$2.31	$1,214,782,130	7 / 9
2026-07-30	$2.31	$1,214,782,130	7 / 9
2026-07-31	$2.31	$1,214,782,130	7 / 9
2026-08-01	$2.14	$1,214,782,094	7 / 7
2026-08-02	$2.31	$1,214,782,130	7 / 9
2026-08-03	$2.31	$1,214,782,130	7 / 9
2026-08-04	$2.31	$1,214,782,130	7 / 9
2026-08-05	$2.31	$1,214,782,130	7 / 9
2026-08-06	$2.37	$1,215,837,680	6 / 9
2026-08-07	$2.21	$1,235,491,759	6 / 7
2026-08-08	$2.29	$1,235,527,910	7 / 9
2026-08-09	$2.29	$1,235,527,910	7 / 9
2026-08-10	$2.21	$1,235,491,759	6 / 7
2026-08-12	$2.21	$1,235,491,759	6 / 7
2026-08-13	$2.29	$1,225,786,200	7 / 8
2026-08-14	$2.21	$1,235,491,759	6 / 7
2026-08-15	$2.21	$1,235,491,759	7 / 7
2026-08-16	$2.21	$1,235,491,759	7 / 7
2026-08-17	$2.21	$1,235,491,759	7 / 7
2026-08-18	$2.21	$1,235,491,759	7 / 7
2026-08-19	$2.21	$1,235,491,759	7 / 7
2026-08-20	$2.27	$1,245,056,204	6 / 7
2026-08-21	$2.27	$1,245,056,204	6 / 7
2026-08-22	$2.27	$1,245,056,204	6 / 7
2026-08-23	$2.27	$1,245,056,204	6 / 7
2026-08-24	$2.27	$1,245,056,204	6 / 7
2026-08-25	$2.27	$1,245,056,204	6 / 7
2026-08-26	$2.27	$1,245,056,204	6 / 7
2026-08-27	$2.27	$1,245,056,204	6 / 7
2026-08-28	$2.27	$1,245,056,204	6 / 7
2026-08-29	$2.27	$1,245,056,204	6 / 7
2026-08-30	$2.27	$1,245,056,204	6 / 7
2026-08-31	$2.27	$1,245,056,204	6 / 7
2026-09-01	$2.27	$1,245,056,179	6 / 7
2026-09-02	$2.27	$1,245,056,179	6 / 7
2026-09-03	$2.27	$1,245,056,179	6 / 7
2026-09-04	$2.27	$1,245,056,179	6 / 7
2026-09-05	$2.27	$1,245,056,179	6 / 7
2026-09-06	$2.27	$1,245,056,179	6 / 7
2026-09-07	$2.27	$1,245,056,179	6 / 7
2026-09-08	$2.27	$1,245,056,179	6 / 7
2026-09-09	$2.27	$1,245,056,179	6 / 7
2026-09-10	$2.27	$1,245,056,179	6 / 7
2026-09-11	$2.27	$1,245,056,179	6 / 7
2026-09-12	$2.27	$1,245,056,179	6 / 7
2026-09-13	$2.27	$1,245,056,179	6 / 7
2026-09-14	$2.27	$1,245,056,179	6 / 7
2026-09-15	$2.27	$1,245,056,179	6 / 7
2026-09-16	$2.27	$1,245,056,179	6 / 7
2026-09-17	$2.27	$1,245,056,179	6 / 7
2026-09-18	$2.27	$1,245,056,179	6 / 7
2026-09-19	$2.27	$1,245,056,179	6 / 7
2026-09-20	$2.27	$1,245,056,179	6 / 7
2026-09-21	$2.27	$1,245,056,179	6 / 7
2026-09-22	$2.27	$1,245,056,179	6 / 7
2026-09-23	$2.27	$1,245,056,179	6 / 7
2026-09-24	$2.27	$1,245,056,179	6 / 7
2026-09-25	$2.25	$1,240,499,355	6 / 7
2026-09-26	$2.25	$1,240,499,355	6 / 7
2026-09-27	$2.25	$1,240,499,355	6 / 7
2026-09-28	$2.25	$1,240,499,355	6 / 7
2026-09-29	$2.25	$1,240,499,355	6 / 7
2026-09-30	$2.25	$1,240,499,355	6 / 7
2026-10-01	$2.25	$1,240,499,355	6 / 7
2026-10-02	$2.25	$1,240,499,355	6 / 7
2026-10-03	$2.25	$1,240,499,355	6 / 7
2026-10-04	$2.25	$1,240,499,355	6 / 7
2026-10-05	$2.25	$1,240,499,355	6 / 7
2026-10-06	$2.25	$1,240,499,355	6 / 7
2026-10-07	$2.25	$1,240,499,355	6 / 7
2026-10-08	$2.25	$1,240,499,355	6 / 7
2026-10-09	$2.25	$1,240,499,355	6 / 7
2026-10-10	$2.25	$1,240,499,355	6 / 7
2026-10-11	$2.25	$1,240,499,355	6 / 7
2026-10-12	$2.25	$1,240,499,355	6 / 7
2026-10-13	$2.25	$1,240,499,355	6 / 7
2026-10-14	$2.25	$1,240,499,355	6 / 7
2026-10-15	$2.25	$1,240,499,355	6 / 7
2026-10-16	$2.25	$1,240,499,355	6 / 7
2026-10-17	$2.25	$1,240,499,355	6 / 7
2026-10-18	$2.25	$1,240,499,355	6 / 7
2026-10-19	$2.25	$1,240,499,355	6 / 7
2026-10-20	$2.25	$1,240,499,355	6 / 7
2026-10-21	$2.25	$1,240,499,355	6 / 7
2026-10-22	$2.25	$1,240,461,875	6 / 7
2026-10-23	$2.25	$1,240,461,875	6 / 7
2026-10-24	$2.25	$1,240,461,875	6 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	6	3	1
2026-06-01	6	2	1
2026-07-01	6	2	1
2026-08-01	6	2	1
2026-09-01	6	2	1
2026-10-01	6	2	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 2 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

EPS around $0.40 next quarterPublished status: Broken
Gross margin near 38.5% next quarterPublished status: Under Pressure
Revenue grows to about $275M next quarterPublished status: Broken

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-54.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

IPG Photonics outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a growth-oriented industrial technology business, not a clear turnaround or a stable compounder today. The long-term thesis is on watch: company momentum has improved, but recent financial performance remains below its industry cohort and risk is elevated.

What's priced into IPG Photonics

IPGP is expensive versus peers, with a 1.27 premium, and the valuation evidence points to expectations of a re-rating, meaning investors expect its market valuation to improve. The expectations gap is meaningful, but the evidence says fragility is low because expensive valuation is not paired with weak and turbulent conditions.

What the fundamentals likely do

Near term, a guidance cut would be a notable risk, although the stated miss probability is low and recent earnings surprises have been erratic and trending down. Over the multi-year view, Industrial Solutions revenue has grown 26% from 2025-Q1 to 2026-Q2, while the completed Lumibird Medical acquisition is expected to expand the addressable market and support margins and earnings; those benefits still depend on execution.

What IPG Photonics hinges on

The thesis hinges on continued Industrial Solutions growth and whether IPGP can deliver the expected benefits from Lumibird Medical. Near term, guidance is a key swing factor; broader support could come if the Fed cuts rates or major technology companies continue to report strong results and guidance.